These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34009274)

  • 1. Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis.
    Aldridge J; Andersson K; Gjertsson I; Hultgård Ekwall AK; Hallström M; van Vollenhoven R; Lundell AC; Rudin A
    Rheumatology (Oxford); 2022 Mar; 61(3):1233-1242. PubMed ID: 34009274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
    Hetland ML; Haavardsholm EA; Rudin A; Nordström D; Nurmohamed M; Gudbjornsson B; Lampa J; Hørslev-Petersen K; Uhlig T; Grondal G; Østergaard M; Heiberg MS; Twisk J; Lend K; Krabbe S; Hyldstrup LH; Lindqvist J; Hultgård Ekwall AK; Grøn KL; Kapetanovic M; Faustini F; Tuompo R; Lorenzen T; Cagnotto G; Baecklund E; Hendricks O; Vedder D; Sokka-Isler T; Husmark T; Ljoså MA; Brodin E; Ellingsen T; Söderbergh A; Rizk M; Olsson ÅR; Larsson P; Uhrenholt L; Just SA; Stevens DJ; Laurberg TB; Bakland G; Olsen IC; van Vollenhoven R;
    BMJ; 2020 Dec; 371():m4328. PubMed ID: 33268527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis.
    Bonelli M; Göschl L; Blüml S; Karonitsch T; Hirahara K; Ferner E; Steiner CW; Steiner G; Smolen JS; Scheinecker C
    Rheumatology (Oxford); 2016 Apr; 55(4):710-20. PubMed ID: 26672908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis.
    Aldridge J; Lundell AC; Andersson K; Mark L; Lund Hetland M; Østergaard M; Uhlig T; Schrumpf Heiberg M; Haavardsholm EA; Nurmohamed M; Lampa J; Nordström D; Hørslev-Petersen K; Gudbjornsson B; Gröndal G; van Vollenhoven R; Rudin A
    Clin Exp Rheumatol; 2022 Jul; 40(7):1393-1402. PubMed ID: 34796837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
    Østergaard M; van Vollenhoven RF; Rudin A; Hetland ML; Heiberg MS; Nordström DC; Nurmohamed MT; Gudbjornsson B; Ørnbjerg LM; Bøyesen P; Lend K; Hørslev-Petersen K; Uhlig T; Sokka T; Grondal G; Krabbe S; Lindqvist J; Gjertsson I; Glinatsi D; Kapetanovic MC; Aga AB; Faustini F; Parmanne P; Lorenzen T; Giovanni C; Back J; Hendricks O; Vedder D; Rannio T; Grenholm E; Ljoså MK; Brodin E; Lindegaard H; Söderbergh A; Rizk M; Kastbom A; Larsson P; Uhrenholt L; Just SA; Stevens DJ; Bay Laurbjerg T; Bakland G; Olsen IC; Haavardsholm EA; Lampa J;
    Ann Rheum Dis; 2023 Oct; 82(10):1286-1295. PubMed ID: 37423647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis.
    Liu J; Idborg H; Korotkova M; Lend K; van Vollenhoven R; Lampa J; Rudin A; Nordström D; Gudbjornsson B; Gröndal G; Uhlig T; Hørslev-Petersen K; Lund Hetland M; Østergaard M; Nurmohamed M; Jakobsson PJ
    Arthritis Res Ther; 2024 Mar; 26(1):61. PubMed ID: 38444034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of a Type 2-Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
    Slauenwhite D; McAlpine SM; Hanly JG; Malik A; Haidl ID; Marshall JS; Issekutz TB
    Arthritis Rheumatol; 2020 Jul; 72(7):1091-1102. PubMed ID: 32039570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
    Nakayamada S; Kubo S; Yoshikawa M; Miyazaki Y; Yunoue N; Iwata S; Miyagawa I; Hirata S; Nakano K; Saito K; Tanaka Y
    Rheumatology (Oxford); 2018 Jan; 57(1):164-174. PubMed ID: 28371836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.
    Fukuyo S; Nakayamada S; Iwata S; Kubo S; Saito K; Tanaka Y
    Clin Exp Rheumatol; 2017; 35(4):562-570. PubMed ID: 28516880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
    Smolen JS; Emery P; Ferraccioli GF; Samborski W; Berenbaum F; Davies OR; Koetse W; Purcaru O; Bennett B; Burkhardt H
    Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis.
    Bonelli M; Ferner E; Göschl L; Blüml S; Hladik A; Karonitsch T; Kiener HP; Byrne R; Niederreiter B; Steiner CW; Rath E; Bergmann M; Smolen JS; Scheinecker C
    Arthritis Rheum; 2013 Mar; 65(3):599-607. PubMed ID: 23203906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial.
    Lend K; van Vollenhoven RF; Lampa J; Lund Hetland M; Haavardsholm EA; Nordström D; Nurmohamed M; Gudbjornsson B; Rudin A; Østergaard M; Uhlig T; Grondal G; Hørslev-Petersen K; Heiberg MS; Sokka-Isler T; Koopman FA; Twisk JWR; van der Horst-Bruinsma I
    Lancet Rheumatol; 2022 Oct; 4(10):e688-e698. PubMed ID: 38265967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.
    Lend K; Koopman FA; Lampa J; Jansen G; Hetland ML; Uhlig T; Nordström D; Nurmohamed M; Gudbjornsson B; Rudin A; Østergaard M; Heiberg MS; Sokka-Isler T; Hørslev-Petersen K; Haavardsholm EA; Grondal G; Twisk JWR; van Vollenhoven R
    Arthritis Rheumatol; 2024 Mar; 76(3):363-376. PubMed ID: 37846618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
    Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating CD4
    Zhao L; Li Z; Zeng X; Xia C; Xu L; Xu Q; Song Y; Liu C
    Int J Rheum Dis; 2021 Aug; 24(8):1032-1039. PubMed ID: 34227243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
    Kikuchi J; Hashizume M; Kaneko Y; Yoshimoto K; Nishina N; Takeuchi T
    Arthritis Res Ther; 2015 Jan; 17(1):10. PubMed ID: 25604867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohort.
    Atzeni F; Cacciapaglia F; Galloways J; Manfredi A; Sakellariou G; Norton S; Gremese E; Spinelli FR; Viapiana O; Piga M; Erre GL; Bartoloni Bocci E
    Autoimmun Rev; 2024 Feb; 23(2):103478. PubMed ID: 37956778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.